Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Drug Center Rotates Acting Deputy Director: Throckmorton Replaces Goldberger

This article was originally published in The Pink Sheet Daily

Executive Summary

Acting Center Deputy Director Goldberger will return to duties as director of Office of Drug Evaluation IV May 3, when Cardio-Renal Division Director Throckmorton will take his place. Acting Center Director Galson's letter to CDER staff indicates the center will remain without a permanent director for at least six to 12 months.
Advertisement

Related Content

Throckmorton Named Permanent CDER Deputy Director
Throckmorton Named Permanent CDER Deputy Director

Topics

Advertisement
UsernamePublicRestriction

Register

PS059087

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel